Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry.

Foote JB, Sarvesh S, Emens LA.

Methods Enzymol. 2020;631:1-20. doi: 10.1016/bs.mie.2019.08.015. Epub 2019 Oct 18.

PMID:
31948543
2.

Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.

Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA.

Cancer Treat Rev. 2020 Mar;84:101947. doi: 10.1016/j.ctrv.2019.101947. Epub 2019 Nov 29. Review.

PMID:
31926403
3.

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators.

Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.

PMID:
31786121
4.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).

Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I.

J Immunother Cancer. 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3. Review.

5.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

6.

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.

Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA.

J Immunother Cancer. 2019 Oct 23;7(1):274. doi: 10.1186/s40425-019-0740-8.

7.

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.

Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C, Hall A, Kim R, Pogue-Geile K, Sammons S, Nayyar N, Chukwueke U, Brastianos PK, Anders CK, Soloff AC, Vignali DAA, Tseng GC, Emens LA, Lucas PC, Blackwell KL, Oesterreich S, Lee AV.

J Immunother Cancer. 2019 Oct 18;7(1):265. doi: 10.1186/s40425-019-0755-1.

8.

The dawn of immunotherapy for breast cancer.

Emens LA.

Clin Adv Hematol Oncol. 2019 Jun;17(6):332-335. Review. No abstract available.

PMID:
31437135
9.

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA.

Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. Epub 2019 Jun 14.

PMID:
31204078
10.

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.

Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S.

Mol Imaging. 2019 Jan-Dec;18:1536012119852189. doi: 10.1177/1536012119852189.

11.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.

Schmid P, Chui SY, Emens LA.

N Engl J Med. 2019 Mar 7;380(10):987-988. doi: 10.1056/NEJMc1900150. No abstract available.

PMID:
30855757
12.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
13.

Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.

Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D.

JAMA Ophthalmol. 2019 Jan 1;137(1):96-100. doi: 10.1001/jamaophthalmol.2018.5191.

14.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators.

N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

PMID:
30345906
15.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.

16.

STING signaling: a key to therapeutic tumor immunity.

Foote JB, Emens LA.

Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064. No abstract available.

PMID:
30008260
17.

Targeting adenosine for cancer immunotherapy.

Leone RD, Emens LA.

J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8. Review.

18.

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA, Fiering S.

Breast Cancer Res Treat. 2018 Sep;171(2):273-282. doi: 10.1007/s10549-018-4834-7. Epub 2018 Jun 1.

19.

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.

20.

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.

Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.

21.

Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.

Ojalvo LS, Thompson ED, Wang TL, Meeker AK, Shih IM, Fader AN, Cimino-Mathews A, Emens LA.

Hum Pathol. 2018 Apr;74:135-147. doi: 10.1016/j.humpath.2017.12.010. Epub 2017 Dec 27.

PMID:
29288043
22.

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE.

Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590.

23.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

24.

Breast Cancer Immunotherapy: Facts and Hopes.

Emens LA.

Clin Cancer Res. 2018 Feb 1;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. Epub 2017 Aug 11. Review.

25.

PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA, Cimino-Mathews A.

Mod Pathol. 2017 Nov;30(11):1551-1560. doi: 10.1038/modpathol.2017.79. Epub 2017 Jul 21.

26.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
27.

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA.

Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. Epub 2017 May 8.

28.

Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.

Sunay MM, Foote JB, Leatherman JM, Edwards JP, Armstrong TD, Nirschl CJ, Hicks J, Emens LA.

Int Immunopharmacol. 2017 May;46:112-123. doi: 10.1016/j.intimp.2017.02.028. Epub 2017 Mar 7.

29.

Specific immunotherapy in ovarian cancer: a systematic review.

Alipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, Rezaei N.

Immunotherapy. 2016 Oct;8(10):1193-204. doi: 10.2217/imt-2016-0034. Review.

PMID:
27605068
30.

It's TIME for a biomarker-driven approach to cancer immunotherapy.

Emens LA.

J Immunother Cancer. 2016 Aug 16;4:43. doi: 10.1186/s40425-016-0147-8. eCollection 2016. No abstract available.

31.

Cancer immunotherapy trials: leading a paradigm shift in drug development.

Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL.

J Immunother Cancer. 2016 Jul 19;4:42. doi: 10.1186/s40425-016-0146-9. eCollection 2016. No abstract available.

32.

Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.

VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.

Am J Surg Pathol. 2016 Aug;40(8):1090-9. doi: 10.1097/PAS.0000000000000674.

PMID:
27299796
33.

Targeting the programmed cell death-1 pathway in breast and ovarian cancer.

Emens LA, Kok M, Ojalvo LS.

Curr Opin Obstet Gynecol. 2016 Apr;28(2):142-7. doi: 10.1097/GCO.0000000000000257.

PMID:
26881392
34.

The immune microenvironment of breast ductal carcinoma in situ.

Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA.

Mod Pathol. 2016 Mar;29(3):249-58. doi: 10.1038/modpathol.2015.158. Epub 2016 Jan 15.

35.

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA.

Hum Pathol. 2016 Jan;47(1):52-63. doi: 10.1016/j.humpath.2015.09.003. Epub 2015 Sep 21.

36.

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer.

Emens LA, Romero P.

J Immunother Cancer. 2015 Oct 20;3:49. doi: 10.1186/s40425-015-0092-y. eCollection 2015. No abstract available.

37.

Emerging immunotherapies in ovarian cancer.

Ojalvo LS, Nichols PE, Jelovac D, Emens LA.

Discov Med. 2015 Sep;20(109):97-109. Review.

38.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.

Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Review.

39.

Chemotherapy--A Viable Partner for Cancer Immunotherapy?

Emens LA.

JAMA Oncol. 2015 Nov;1(8):1095-7. doi: 10.1001/jamaoncol.2015.2733. No abstract available.

PMID:
26291503
40.

Immune targeting in breast cancer.

Cimino-Mathews A, Foote JB, Emens LA.

Oncology (Williston Park). 2015 May;29(5):375-85. Review.

41.

The interplay of immunotherapy and chemotherapy: harnessing potential synergies.

Emens LA, Middleton G.

Cancer Immunol Res. 2015 May;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064. Review.

42.

Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.

VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.

Am J Surg Pathol. 2015 Jul;39(7):939-47. doi: 10.1097/PAS.0000000000000424.

PMID:
25871620
43.

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.

Cancer Immunol Res. 2014 Oct;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. Epub 2014 Aug 12.

44.

A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, Emens LA, Argani P.

Hum Pathol. 2013 Nov;44(11):2494-500. doi: 10.1016/j.humpath.2013.06.009. Epub 2013 Jul 31.

45.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

46.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

47.

Chemoimmunotherapy: reengineering tumor immunity.

Chen G, Emens LA.

Cancer Immunol Immunother. 2013 Feb;62(2):203-16. doi: 10.1007/s00262-012-1388-0. Epub 2013 Feb 7. Review.

48.

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Emens LA.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611. doi: 10.1586/era.12.147. Review.

49.

Toward integrative cancer immunotherapy: targeting the tumor microenvironment.

Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J.

J Transl Med. 2012 Apr 10;10:70. doi: 10.1186/1479-5876-10-70.

50.

Re-purposing cancer therapeutics for breast cancer immunotherapy.

Emens LA.

Cancer Immunol Immunother. 2012 Aug;61(8):1299-305. doi: 10.1007/s00262-012-1247-z. Epub 2012 Mar 28. Review.

Supplemental Content

Loading ...
Support Center